Bristol-Myers Squibb Co has a consensus price target of $56.24, established from looking at the 72 latest analyst ratings. The last 3 analyst ratings were released from Wells Fargo, Redburn Atlantic, and B of A Securities on February 6, 2024, February 6, 2024, and January 3, 2024. With an average price target of $55 between Wells Fargo, Redburn Atlantic, and B of A Securities, there's an implied 14.97% upside for Bristol-Myers Squibb Co from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/06/2024 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 6.61% | Wells Fargo | Mohit Bansal | $58 → $51 | Maintains | Equal-Weight | Get Alert |
02/06/2024 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 12.88% | Redburn Atlantic | Steve Chesney | $77 → $54 | Downgrade | Buy → Neutral | Get Alert |
01/03/2024 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 25.42% | B of A Securities | Geoff Meacham | $68 → $60 | Downgrade | Buy → Neutral | Get Alert |
12/27/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 42.14% | B of A Securities | Geoff Meacham | $72 → $68 | Maintains | Buy | Get Alert |
11/15/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 14.97% | Cantor Fitzgerald | Olivia Brayer | $68 → $55 | Downgrade | Overweight → Neutral | Get Alert |
11/09/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 14.97% | Deutsche Bank | James Shin | → $55 | Initiates | → Hold | Get Alert |
11/02/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 12.88% | Daiwa Capital | Narumi Nakagiri | $68 → $54 | Downgrade | Outperform → Neutral | Get Alert |
10/30/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 44.23% | Goldman Sachs | Chris Shibutani | $81 → $69 | Maintains | Buy | Get Alert |
10/27/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 4.52% | Morgan Stanley | Terence Flynn | $56 → $50 | Maintains | Underweight | Get Alert |
10/27/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 6.61% | Barclays | Carter Gould | $60 → $51 | Maintains | Equal-Weight | Get Alert |
10/27/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 25.42% | BMO Capital | Evan Seigerman | → $60 | Downgrade | Outperform → Market Perform | Get Alert |
10/27/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | — | William Blair | Matt Phipps | — | Downgrade | Outperform → Market Perform | Get Alert |
10/27/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 10.79% | HSBC | Rajesh Kumar | $55 → $53 | Upgrade | Reduce → Hold | Get Alert |
10/20/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 25.42% | UBS | Trung Huynh | $70 → $60 | Assumes | Neutral → Neutral | Get Alert |
10/11/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 17.06% | Morgan Stanley | Terence Flynn | $57 → $56 | Maintains | Underweight | Get Alert |
10/09/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 56.77% | Cantor Fitzgerald | Olivia Brayer | → $75 | Reiterates | Overweight → Overweight | Get Alert |
10/06/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 75.59% | Truist Securities | Robyn Karnauskas | → $84 | Reiterates | Buy → Buy | Get Alert |
09/15/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 75.59% | Truist Securities | Gregg Gilbert | → $84 | Reiterates | Buy → Buy | Get Alert |
09/15/2023 | BMY | Buy Now | Bristol-Myers Squibb | $47.84 | 37.96% | TD Cowen | Steve Scala | $80 → $66 | Maintains | Market Perform | Get Alert |
The latest price target for Bristol-Myers Squibb (NYSE: BMY) was reported by Wells Fargo on February 6, 2024. The analyst firm set a price target for $51.00 expecting BMY to rise to within 12 months (a possible 6.61% upside). 35 analyst firms have reported ratings in the last year.
The latest analyst rating for Bristol-Myers Squibb (NYSE: BMY) was provided by Wells Fargo, and Bristol-Myers Squibb maintained their equal-weight rating.
The last upgrade for Bristol-Myers Squibb Co happened on October 27, 2023 when HSBC raised their price target to $53. HSBC previously had a reduce for Bristol-Myers Squibb Co.
The last downgrade for Bristol-Myers Squibb Co happened on February 6, 2024 when Redburn Atlantic changed their price target from $77 to $54 for Bristol-Myers Squibb Co.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bristol-Myers Squibb, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bristol-Myers Squibb was filed on February 6, 2024 so you should expect the next rating to be made available sometime around February 6, 2025.
While ratings are subjective and will change, the latest Bristol-Myers Squibb (BMY) rating was a maintained with a price target of $58.00 to $51.00. The current price Bristol-Myers Squibb (BMY) is trading at is $47.84, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.